Clinical Trials Browser

Phase 1 × Interventional × CLR1404 × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03478462 2026-03-18

CLOVER-2

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05610891 2026-03-18

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Phase 1 Active not recruiting

50 enrolled

CNS

Glioma

NCT04105543 2025-09-02

CLR 131 Combined With Radiation for Head and Neck Cancer

Phase 1 Completed

12 enrolled 27 charts

Head & Neck

Head and Neck Neoplasms

NCT02278315 2023-02-22

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

31 enrolled

Plasma cell

Multiple Myeloma

NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Phase 1 Completed

12 enrolled

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00925275 2010-05-04

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

Phase 1 Completed

9 enrolled

Neoplasms, Recurrence

Clinical Trials

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

CLOVER-2

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

CLR 131 Combined With Radiation for Head and Neck Cancer

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors